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pDITORIAL COMMENT
he Cardiologist’s
oolbox: Improving Care*
ri Ben-Yehuda, MD, FACC
an Diego, California
hen patients seek medical advice and care, they assume
hat their physicians will apply the latest scientific informa-
ion to both their diagnosis and treatment (1). And al-
hough “evidence-based medicine” may not yet be a com-
on phrase in the waiting room (2), the increasing
vailability of medical information, through both the tradi-
ional media outlets and the Internet, will only undoubtedly
ncrease the rightful expectation of patients to receive the
est care possible.
Cardiology as a specialty has been particularly blessed by
he availability of evidence-based medicine. Indeed, the
dvent of the large-scale, placebo-controlled trial has been a
articular cardiology phenomenon. The care of acute myo-
ardial infarction (AMI) has been revolutionized by the
doption of revascularization strategies (both thrombolysis
See page 2166
nd primary percutaneous intervention) for ST-segment
levation myocardial infarctions (STEMI), as well as sec-
ndary prevention strategies. The latter include antiplatelet
herapy (particularly aspirin), beta-blockers, angiotensin-
onverting enzyme inhibitors, lipid-lowering therapy (par-
icularly statins), along with crucial lifestyle modifications,
uch as diet intervention, exercise, and smoking cessation
3). It has been estimated that the additive effects of these
nterventions can lead to an 80% reduction in events (4).
The use of aggressive lipid-lowering therapy for second-
ry prevention after myocardial infarction (MI) illustrates
he marked changes that have occurred in the past two
ecades. Initially viewed by physicians with skepticism (5),
he results of landmark clinical trials, including the Scandi-
avian Simvastatin Survival Study (4S) (6) and Cholesterol
nd Recurrent Events (CARE) (7) trial, firmly proved the
mportance of lipid-lowering therapy for secondary preven-
ion. Recently, the 20,536-patient Heart Protection Study
8), which included 3,421 patients with low-density li-
oprotein (LDL) 100 mg/dl at entry, showed similar
eductions in cardiovascular events compared with patients
ith higher LDL levels, thus extending the benefit to
atients who until recently were not considered candidates
or therapy.
Although the findings of the Heart Protection Study have
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.oFrom the University of California, San Diego, San Diego, California.ot yet been incorporated into national guidelines, the
urrent American College of Cardiology (ACC)/American
eart Association (AHA) AMI guidelines, as well as the
holesterol-specific Adult Treatment Panel III guidelines of
he National Cholesterol Education Program, already pro-
ide a clear mandate to treat post-MI patients aggressively
or secondary prevention. Yet despite these guidelines,
umerous studies (9,10) continue to document significant
reatment gaps. The continued deficiencies in the health
are system, epitomized in the lack of adherence in post-MI
are, has led the Institute of Medicine in 2001 to label the
roblem as not only a quality gap but a “quality chasm” (1).
The realization that without significant improvement in
he implementation of prevention strategies, particularly in
he high-risk secondary prevention population, we will not
ake significant headway in lowering the morbidity and
ortality of coronary disease, has led various organizations
o both point out the problem as well as initiate programs to
ry to close treatment gaps. In this endeavor, credit is due to
he pioneering efforts of Dr. Greg Fonarow, who in 1994
aunched the Cardiac Hospitalization Atherosclerosis
anagement Program at the University of California-Los
ngeles, to improve compliance with post-MI care (11).
Both the AHA and the ACC have launched initiatives
imed at improving the implementation of secondary pre-
ention therapies. Both organizations have rightfully chosen
he hospital environment for the initial efforts because the
ospitalized MI patient represents the “low-hanging fruit.”
oreover, studies have indicated better compliance when
herapies are initiated during the index hospitalization (12).
The contribution of the ACC to this important quality
ssue is the aptly named GAP projects, for Guidelines
pplied in Practice. Initially piloted in Michigan three years
go, the project has now been extended to several states.
ne particularly important finding from the pilot study was
n association between the use of standardized AMI orders
nd improved adherence to early quality indicators, such as
he administration of aspirin or lipid measurements within
4 h of admission. Similarly, the use of standardized
ischarge orders was associated with excellent adherence
80% to 90%) to late indicators, such as the use of
ipid-lowering drugs, aspirin, beta-blockers, angiotensin-
onverting enzyme inhibitors, as well as lifestyle counseling.
nfortunately, the use of these tools was documented in
nly one-quarter of the patients (13).
The follow-up GAP study in Michigan, which is re-
orted in this issue of the Journal by Mehta et al. (14),
herefore focused on increasing the use of tools, such as care
athways, standardized AMI admission, and discharge or-
ers. Significant efforts were made to educate providers
both physicians and nurses), identify barriers, and assemble
multidisciplinary team that would be able to impact the
rocess of care in the hospitals.
On the whole, the findings are gratifying: use of at leastne tool increased to 93% of patients and, as predicted, tool
u
l
p
p
t
s
a
s
t
s
a
o
b
b
t
m
c
t
h
s
u
i
t
a
a
i
m
e
p
T
b
w
t
s
t
i
A
d
l
s
p
m
b
s
b
e
c
Y
w
s
S
a
r
S
p
r
m
t
b
a
t
n
f
d
s
l
m
H
e
m
n
i
s
t
r
c
t
i
m
t
n
n
m
a
s
n
b
l
d
r
c
m
s
a
R
U
D
R
2175JACC Vol. 43, No. 12, 2004 Ben-Yehuda
June 16, 2004:2174–6 Editorial Commentse was associated with increased adherence to the guide-
ines. Notable exceptions include low rates of adherence in
atients undergoing bypass surgery, with only one-half of
ost-coronary artery bypass grafting (CABG) eligible pa-
ients receiving a statin. Even in the non-CABG patients,
ignificant areas for improvement remain: whereas standard
dmission orders were used in 82% of patients overall,
tandard discharge orders were used in only 47%.
Disease management efforts are time-consuming and
edious, and for many lack the excitement of traditional new
cientific discovery, whether clinical or basic. However, it is
lso self evident that treatments not prescribed remain of
nly theoretical benefit. Therefore, the authors and mem-
ers of the AMI GAP project should be congratulated on
oth their devotion and success.
There are some important limitations, however, to both
his particular study as well as other attempts at disease
anagement. The study by Mehta et al. (14) used historical
ontrols from approximately one year earlier. During this
ime period, physician adherence to AMI guidelines may
ave increased independently of the intervention. The
tudy, however, again confirmed an association between the
se of standard tools and quality indicators, suggesting that
ndeed the improvements observed were to a large degree
he result of the initiative itself. More importantly, the data
re only indicative of prescribing patterns up to discharge,
nd long-term compliance is not assured.
More fundamental questions arise in considering the
mpact of guidelines in general and their role in clinical
edicine. Although undoubtedly the implementation of
vidence-based medicine can improve the health of the
opulation targeted as a whole, individual results may differ.
he effect of an intervention may be known on a population
asis but always remains an “experiment in regard to the
ell-being of that individual patient” (15). Indeed, the trend
oward standard guideline-based medicine is, in some re-
pects, in direct conflict with another vision in medicine—
he vision of individually targeted therapy based on our
ndividual uniqueness. The case of statins is illustrative.
lthough the overall benefit of statins is unquestionable and
oes not even appear to be dependent on baseline LDL
evels, data from one of the landmark studies, the 4S study,
uggests that not all patients benefit equally. In the 4S study
atients who were hyperabsorbers of cholesterol, as deter-
ined by higher blood cholestanol levels, did not appear to
enefit from the use of simvastatin (16).
The critical physician/scientist may also question whether
pecific therapies, endorsed with broad strokes, are applica-
le to today’s patients. Acute use of beta-blockers are
ndorsed in the guidelines for every AMI patient without
lear contraindications, such as bradycardia or asthma (3).
et the trials that these recommendations are based upon
ere performed before the era of revascularization. In the
etting of primary percutaneous coronary intervention for
TEMI, there has been little prospective randomized data
vailable (17), although three retrospective articles (18–20)ecently published in the Journal point to a potential benefit.
imilarly, the long-term benefit of beta-blockers in low-risk
atients, particularly those who have undergone complete
evascularization, is still unclear, despite the overall endorse-
ent by the guidelines (as a class IIa indication). Data from
he Beta-Blocker Heart Attack Trial (21), performed even
efore the era of percutaneous coronary intervention, actu-
lly indicated a lack of benefit in what was defined at the
ime as “nontransmural MI.” Given the potential for sig-
ificant side effects with beta-blockers (such as impotence,
atigue, and decreased exercise tolerance), there will un-
oubtedly be situations in which the benefits may not be
ufficient to outweigh other considerations such as quality of
ife.
What is the conscientious cardiologist to do in the face of
ounting and overall laudable efforts to standardize care?
ow does one practice medicine as an art in the age of
vidence-based medicine? One critic of evidence-based
edicine has warned against “an environment in which
umbers, not patients, are treated and in which the best
nterest of individual patients is subordinated to some
tatistical standard” (22). Here again, the use of appropriate
ools may actually be of help, provided they serve as a
eminder and a quality check rather than mandating a
ertain course of action in abeyance of clinical judgment. In
his regard, they should also serve as documentation tools to
ndicate whether and why a particular evidence-based treat-
ent is either prescribed or withheld.
The AMI GAP project (14) was funded by grants from
he ACC and pharmaceutical companies. Although we are
ot told of the exact cost and a cost-effectiveness analysis is
ot presented in the report, it is clear that disease manage-
ent efforts require both tremendous organizational efforts
nd significant funding, which is often lacking.
Moreover, the present study (14) used a paper-based
ystem. Indeed, the American health care system, with the
otable exception of insurance claims, is still woefully
ehind in the implementation of information technology,
agging far behind other sectors in society. Integrating
isease management processes into an electronic medical
ecord, while allowing for the individualization of medical
are and incorporation of new scientific information, re-
ains a mighty challenge. The GAP project is an important
tep in the long road toward quality in medicine in general
nd cardiology in particular.
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niversity of California, San Diego, 200 West Arbor Drive, San
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